Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients by Parisi S, Finelli C

Get full text

Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) by Cappellini, A, Mongiorgi, S, Finelli, C, Fazio, A, Ratti, S, Marvi, MV, Curti, A, Salvestrini, V, Pellagatti, A, Billi, AM, Suh, P-G, McCubrey, JA, Boultwood, J, Manzoli, L, Cocco, L, Follo, MY

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes by Follo, M, Pellagatti, A, Armstrong, R, Ratti, S, Mongiorgi, S, De Fanti, S, Bochicchio, M, Russo, D, Gobbi, M, Miglino, M, Parisi, S, Martinelli, G, Cavo, M, Luiselli, D, McCubrey, J, Suh, P, Manzoli, L, Boultwood, J, Finelli, C, Cocco, L

Luspatercept in patients with lower-risk myelodysplastic syndromes by Fenaux, P, Platzbecker, U, Mufti, GJ, Garcia-Manero, G, Buckstein, R, Santini, V, Díez-Campelo, M, Finelli, C, Cazzola, M, Ilhan, O, Sekeres, MA, Falantes, JF, Arrizabalaga, B, Salvi, F, Giai, V, Vyas, P, Bowen, D, Selleslag, D, DeZern, AE, Jurcic, JG, Germing, U, Götze, KS, Quesnel, B, Beyne-Rauzy, O, Cluzeau, T, Voso, M-T, Mazure, D, Vellenga, E, Greenberg, PL, Hellström-Lindberg, E, Zeidan, AM, Adès, L, Verma, A, Savona, MR, Laadem, A, Benzohra, A, Zhang, J, Rampersad, A, Dunshee, DR, Linde, PG, Sherman, ML, Komrokji, RS, List, AF